Candida is the most common isolate of keratitis

Article

In a review of culture-positive fungal keratitis seen at Moorfields Eye Hospital, London, UK, over a 13-year period, Candida has been identified as the principal isolate.

In a review of culture-positive fungal keratitis seen at Moorfields Eye Hospital, London, UK, over a 13-year period, Candida has been identified as the principal isolate, according to the results of a study published in the October issue of Cornea.

Stephen Tuft and colleagues retrospectively identified isolates from laboratory reports and reviewed the clinical records. The fungal type, risk factors for infection, in vitro sensitivity and clinical outcome were recorded.

The researchers found 66 isolates from 65 patients, 40 of which were subspecies of Candida. The average interval from the onset of keratitis to confirmation of fungal infection was 3.4 weeks. Prior ocular surface disease or a penetrating keratoplasty (PK) was present in 97.4% of patients with Candida infection and 74.4% of patients with Candida infection were using topical steroids at the time of diagnosis.

The principal risk factors for filamentary fungal infection were trauma (30.8%) or cosmetic contact lens wear (30.8%), with ocular surface disease or a prior PK present in five (19.2%) cases.

The results of this review suggest that Candida is the principal isolate and is usually found in eyes with ocular surface disease or a prior PK treated with topical steroids.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.